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DOI 10.1016/j.ccr.2010.10.022SUMMARYHdac3 is essential for efficient DNA replication and DNA damage control. Deletion of Hdac3 impaired DNA
repair and greatly reduced chromatin compaction and heterochromatin content. These defects corre-
sponded to increases in histone H3K9,K14ac; H4K5ac; and H4K12ac in late S phase of the cell cycle, and
histone deposition marks were retained in quiescent Hdac3-null cells. Liver-specific deletion of Hdac3
culminated in hepatocellular carcinoma. Whereas HDAC3 expression was downregulated in only a small
number of human liver cancers, the mRNA levels of the HDAC3 cofactor NCOR1 were reduced in one-third
of these cases. siRNA targeting of NCOR1 and SMRT (NCOR2) increased H4K5ac and caused DNA damage,
indicating that the HDAC3/NCOR/SMRT axis is critical for maintaining chromatin structure and genomic
stability.INTRODUCTION
Histone deacetylases (HDACs) play major roles in modulating
chromatin accessibility during transcription, replication, recom-
bination, and repair (Gallinari et al., 2007; Goodarzi et al.,
2009), yet the role of individual HDACs in these processes is still
unclear. Deacetylation of histones is required for re-establishing
chromatin structure on a local basis after transcription of a gene
or after the repair of a DNA double-strand break (TsukamotoSignificance
Broad-spectrum histone deacetylase inhibitors (HDI) are being
itors are being developed for therapeutic uses. Genetic analys
understand the action of these inhibitors and their potential side
of all currently used HDIs, causes genomic instability, and dele
These phenotypes correlate with global increases in the acety
structure, and a loss of heterochromatin. Our results genetica
critical cell-cycle functions and genomic stability.
436 Cancer Cell 18, 436–447, November 16, 2010 ª2010 Elsevier Incet al., 1997). On a global scale, HDACs act during DNA replica-
tion when the cellular histone content is doubled, as these newly
synthesized histones are acetylated prior to their deposition
onto nascent DNA. The residues most commonly associated
with this process are H4K5ac and H4K12ac (Sobel et al., 1995;
Taddei et al., 1999). These modifications presumably allow
histone chaperones to configure the nucleosome correctly
before deacetylation stabilizes the nucleosome and/or allows
higher-order compaction of the chromatin and the formation ofused to treat a variety of cancers, and more selective inhib-
is of individual histone deacetylases (HDACs) is essential to
effects.We show that inactivation ofHdac3, a central target
tion of Hdac3 in the liver leads to hepatocellular carcinoma.
lation of specific histone residues, disruptions in chromatin
lly link the HDAC3/NCOR/SMRT axis to the maintenance of
.
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Hdac3 Is Required for Genomic Stabilityheterochromatin (Luger et al., 1997; Luger and Richmond, 1998;
Neumann et al., 2009; Verreault et al., 1996).
This process of histone acetylation/deacetylation is required
for genomic stability and cell viability, as perturbations in
the acetyltransferase or components of this pathway cause
genomic instability and result in a failure to recover from geno-
toxic stress (Clarke et al., 1999; Han et al., 2007; Smith et al.,
1998; Yuan et al., 2009). This is a dynamic process that occurs
across the entire genome, and the role of HDACs in the
re-establishment of chromatin structure after replication is
one of the least explored areas of their action. As such, genetic
methods have been the most informative approaches to
understand the physiological role of these critical regulatory
enzymes.
Targeting enzymes that control chromatin structure and
topography has been an extremely valuable tool in cancer
therapy. A wide variety of general and specific small-molecule
inhibitors targeted toward HDACs are currently in clinical trials
and are used as therapies for both solid and hematological
tumors (Bolden et al., 2006). At therapeutic doses, histone
deacetylase inhibitors (HDIs) not only cause cell-cycle-depen-
dent DNA damage but also affect DNA repair, which sensitizes
cells to ionizing radiation (IR), topoisomerase inhibitors, and
cisplatin (Baschnagel et al., 2009; Marchion et al., 2004; Suzuki
et al., 2009). However, the molecular mechanism for inefficient
DNA repair following HDI treatment is still not clear. Given the
high levels of histone acetylation that accumulate in the context
of these inhibitors, it is reasonable to assume that disruption of
chromatin structure may contribute to cell death. As more selec-
tive HDAC inhibitors are moving into clinical trials, it is important
to elucidate the function of individual HDACs to design better
and more specific drugs for cancer therapy and to understand
the mechanism(s) of action or side effects.
Hdac3, a class I HDAC, associates with the nuclear hormone
corepressors NCOR and SMRT (Codina et al., 2005) and is
generally thought of as a locus-specific corepressor that is
recruited to promoters to repress genes regulated by nuclear
hormone receptors and other transcription factors (Jones and
Shi, 2003). In yeast, Snt1 and Hos2 have features of NCOR/
SMRT and Hdac3, respectively (Pijnappel et al., 2001). This
suggests a more ancestral and fundamental role of these
proteins perhaps in the cell cycle, and that this machinery is
also used for gene-specific transcriptional regulation. In agree-
ment with this hypothesis, conditional deletion of Hdac3 in
mouse models demonstrated that murine embryonic fibroblasts
(MEFs) required Hdac3 for cell viability (Bhaskara et al., 2008).
The observed apoptosis was associated with an impaired
S phase progression and DNA double-strand breaks, rather
than altered transcriptional programs (Bhaskara et al., 2008).
The DNA damage was blocked when cells were taken out of
the cell cycle by serum starvation, which suggested that
Hdac3 acts during the S phase (Bhaskara et al., 2008). We
propose that the cell-cycle functions of HDAC3 and its regula-
tory factors NCOR and SMRT may be the ancestral role
and that disruption of these cell-cycle functions may have
dramatic consequences for the regulation of chromatin struc-
ture and genomic stability. These roles may impact the useful-
ness of HDAC3 as a therapeutic target in cancer and other
diseases.CanRESULTS
Hdac3 Function Is Required for Efficient DNA Repair
The inactivation of Hdac3 resulted in increased sensitivity of
quiescent MEFs to ionizing radiation, suggesting a defect
predominantly in nonhomologous end joining (NHEJ)-mediated
repair in these cells (Bhaskara et al., 2008). To test whether these
defects were due to altered DNA repair functions or due to
altered histone modifications and the ensuing changes in chro-
matin structure, we examined whether the inactivation of
Hdac3 increases the sensitivity of Hdac3-null cells to other
DNA-damaging agents. For this purpose, we treated Hdac3FL/+
and Hdac3FL/ MEFs carrying a tamoxifen-inducible ER-Cre
allele with either increasing concentrations of doxorubicin or
cisplatin 48 hr after the addition of 4-hydroxytamoxifen to inacti-
vate Hdac3. Doxorubicin inhibits topoisomerase II (Swift et al.,
2006) and triggers S phase-associated DNA double-strand
breaks that are repaired by the homologous recombination
(HR) pathway, whereas cisplatin crosslinks DNA to form intra-
strand adducts (Siddik, 2003). Inactivation of Hdac3 increased
the sensitivity of MEFs to doxorubicin (Figure 1A) and cisplatin
(Figure 1B), suggesting that in the absence of Hdac3, these
DNA repair pathways are inefficient.
Given thatHdac3 deletion appeared to affect two independent
types of DNA repair, we examined whether Hdac3 plays a role
in the two major NHEJ and HR double-strand-break repair
pathways. We employed a chromosomally integrated reporter
allele system established in HEK293 cells (Figures 1C and 1D)
and used siRNAs to deplete the endogenous levels of HDAC3
(Figure 1E) prior to cutting the reporter site with the I-Sce1
homing endonuclease. The efficiency of rejoining I-Sce1-
cleaved sites was measured using quantitative PCR for NHEJ
and by flow cytometry for reconstituted GFP expression for HR.
In both cases, the reduction in Hdac3 levels caused a 50%–
60% decrease in DNA repair (Figures 1F and 1G), indicating
that Hdac3 is essential for efficient NHEJ- and HR-mediated
repair.
Although Hdac3 has been linked to NHEJ due to its associa-
tion with the SMRT/Ku70 complex (Yu et al., 2006), our DNA
damage sensitivity and repair data suggested that Hdac3 loss
affects DNA repair by targeting an element that is common to
multiple types of DNA repair. Moreover, Hdac3 is not recruited
to the sites of double-strand breaks following IR treatment (see
Figure S1 available online), nor did its loss affect the localization
of other members of the DNA damage response (Rad50, Brca1,
Mdc1, andMre11; data not shown). One of the key histonemodi-
fications that contributes to the DNA damage response, the first
step in double-strand-break repair, is H3K9 trimethylation
(H3K9me3), which recruits the histone acetyltransferase Tip60
(Sun et al., 2009) and other factors involved in the damage
response (e.g., HP1b; Ayoub et al., 2008). Therefore, we tested
whether siRNA targeting of HDAC3 would alter histone acetyla-
tion at the site of an integrated reporter. Chromatin immunopre-
cipitation employing anti-H3K9,K14ac showed that histone
acetylation was increased at the substrate locus at a level
consistent with global changes in H3K9,K14ac (see below),
along with a concomitant decrease in H3K9me3 (Figure 1H),
suggesting that global changes in histone modifications could
contribute to the defects in DNA repair.cer Cell 18, 436–447, November 16, 2010 ª2010 Elsevier Inc. 437
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Figure 1. Loss of Hdac3 Impairs DNARepair
(A and B) MEFs (Hdac3FL/+ and Hdac3FL/) were
treated with 0.1 mM tamoxifen for 48 hr and then
treated with increasing concentrations of either
doxorubicin (A) or cisplatin (B) and cell viability
was measured with the WST-1 assay. Values in
the graphs represent means ± SD of triplicate
samples and the experiment was repeated at least
twice.
(C) A schematic representation of the NHEJ
substrate (left), the product formed (right), and
the position of real-time PCR primers used to
detect the repaired product (Zhuang et al., 2009).
(D) The reporter cassette used for HR detection is
shown schematically. Upon induction of I-Sce1,
gene conversion reconstitutes active GFP. The
repaired GFP was then measured by FACS
analysis.
(E) Western blot analysis of Hdac3 following non-
targeting (NT) or Hdac3 siRNA transfection in
293T cells. GAPDH is shown as a loading control.
(F and G) Chromatin-based repair assays per-
formed in 293T cells following knockdown of
Hdac3 to measure the efficiency of NHEJ using
quantitative PCR (F) and HR using FACS (G). The
values shown in (F) and (G) are the means ± SEM.
(H) Chromatin immunoprecipitation analysis of
H3K9,K14ac and H3K9me3 at the NHEJ substrate
before and after siRNA suppression of Hdac3.
Quantitative PCR was used to compare the
effects of nontargeting and Hdac3 siRNAs, and
the graph shows the average of the relative levels
of H3K9,K14ac ± SD.
See also Figure S1.
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Hdac3 Is Required for Genomic StabilityInactivation of Hdac3 Alters Chromatin Structure
and Decreases Global Heterochromatin
H3K9me3 is one of the best marks of heterochromatin. The
decrease in H3K9me3 upon siRNA-mediated suppression of
HDAC3 or Hdac3 deletion in the liver (Figure 1H; see below)
prompted us to use the Albumin-Cre transgene to delete
Hdac3 in vivo to examine chromatin structure. Initially, we used
transmission electron microscopy to examine the nuclei from
Alb-Cre:Hdac3+/ and Alb-Cre:Hdac3/ postnatal day 17
(p17) livers (Figure 2A). As expected, in control nuclei the elec-
tron-dense heterochromatin was found at the nuclear periphery
(Figure 2A). In contrast, Alb-Cre:Hdac3/ p17 liver nuclei
showed a significant decrease in the amount of heterochromatin,
especially at the periphery (Figure 2A; note that the residual elec-
tron-dense material remaining is consistent with the presence of
nucleoli). A similar result was obtained by enumerating the438 Cancer Cell 18, 436–447, November 16, 2010 ª2010 Elsevier Inc.Hoechst staining of heterochromatic foci
that are evident in fluorescence micros-
copy in mouse cells. Alb-Cre:Hdac3/
liver nuclei showed significantly fewer
foci (Figure 2B). Moreover, when cell frac-
tionation was used to isolate chromatin,
immunoblot analysis demonstrated that
Alb-Cre:Hdac3/ hepatocytes con-
tained roughly 2-fold less HP1b on chro-
matin (Figure 2C). At the gene-specificlevel, we used chromatin immunoprecipitation to examine
H3K9,K14ac at the p53 locus (Su et al., 2009). Inactivation of
Hdac3 caused the accumulation of acetylated H3K9,K14 at
the promoter, upstream of the promoter, within intron 1, and
within the body of the gene (Figure S1), which is consistent
with global changes in chromatin structure and histonemodifica-
tions. Thus, Hdac3 is required for maintaining chromatin struc-
ture in vivo.
Given the reduction in heterochromatin, we used micrococcal
nuclease (MNase) digestion to examine nucleosomal compac-
tion. Digestion of isolated nuclei with increasing concentrations
of MNase demonstrated that the bulk chromatin from Hdac3/
hepatocytes was more sensitive to MNase digestion when
compared to the chromatin fromcontrol hepatocytes (Figure 2D),
indicating that global chromatin structure was altered and is
more ‘‘open’’ in the absence of Hdac3. In addition, we noted
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Figure 2. Loss of Hdac3 Alters Chromatin Structure and Decreases
Heterochromatin
(A) Histological sections prepared from control and Hdac3-null livers at post-
natal day 17 (p17) were used to examine nuclei using electron microscopy.
Control hepatocytes contain dense staining of condensed chromatin, whereas
Hdac3-null cells have decreased amounts of heterochromatin, especially at
the nuclear periphery. Arrowheads indicate the RNA-rich nucleoli that remain
in the Hdac3-null cells. The scale bar represents 4 mm.
(B) Loss of heterochromatic foci upon inactivation of Hdac3. Left panels show
two examples of histological sections from control andHdac3-null liver stained
with Hoechst to detect heterochromatic foci. The scale bar represents 20 mm.
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Canthat the amount of DNA associated with mononucleosomes did
not increase with increasing concentrations of MNase, suggest-
ing that the nucleosomal DNA was more accessible in the
absence of Hdac3. Southern blot analysis of these same
samples using major and minor satellite probes or quantitative
PCR for these regions showed modest sensitivity without
a change in nucleosomal spacing (Figure S2) (Gilbert and Allan,
2001; Sugimura et al., 2010). Given the apparent sensitivity of
mononucleosomal DNA to MNase (Figure 2D), we tested the
sensitivity of nucleosomes to ionic conditions by extracting
histones with differing concentrations of salt. Consistent with
prior results (Li et al., 1993), histone H3 was resistant to NaCl
concentrations up to 1.2 M in control hepatocytes, but in the
absence of Hdac3, histone H3 was nearly completely soluble
in 900 mM NaCl, suggesting that nucleosome integrity was
altered in Hdac3/ hepatocytes.
Structural determinations of the nucleosome show that the
basic lysine residues in histone tails can potentially associate
with DNA, but more likely mediate contacts with acidic surfaces
on adjacent nucleosomes to allow nucleosome compaction and
fiber formation (Luger et al., 1997; Luger and Richmond, 1998;
Schalch et al., 2005). Therefore, we performed western blot
analysis of nuclear extracts prepared from Alb-Cre:Hdac3+/
or Alb-Cre:Hdac3/ p17 livers to examine global histone
acetylation and methylation marks that neutralize the lysine
charges and that regulate chromatin structure. Hdac3 deacety-
lates H4K5ac and H4K12ac in vitro (Johnson et al., 2002), and
loss of Hdac3 resulted in an accumulation of H4K5ac,
H4K12ac, and H4K16ac, as well as H3K9,K14ac, with little effect
on the acetylation of other residues (Figure 3) (Knutson et al.,
2008). Examination of histone methylation demonstrated that
H3K9me3 (Lachner et al., 2001) and H3K79me2 were reduced
(Figure 3), whereas H3K4me3, H3K27me3, and H4K20me2
were unaffected (Figure 3).
H4K5ac and H4K12ac are commonly associated with histone
deposition onto newly synthesized DNA. Given that hepatocytes
are generally quiescent, our liver-specific deletion of Hdac3
implies that Hdac3 is required for removing these marks during
or after DNA synthesis. Therefore, we used Hdac3FL/ NIH 3T3
cells infected with adenovirus expressing Cre to examine these
marks during the cell cycle. Cells were infected with Adeno-
Cre and synchronized in G0/G1 by serum starvation and thenThe graph at the right shows quantification of foci from at least 100 cells for
each sample expressed as the mean ± SEM.
(C) HP1b localization to chromatin is reduced in Hdac3-null livers. Chromatin-
containing fractions were isolated by cell fractionation, and whole-cell lysates
(WCL) or chromatin fractions (Chrom.) were assessed using immunoblot anal-
ysis for HP1b, or histone H3 or b-actin as loading controls. Graph shows quan-
tification of the ratio of HP1b to H3 on chromatin from three independent
experiments expressed as the mean ± SEM.
(D) Nuclei prepared from Alb-Cre:Hdac3+/ control and Alb-Cre:Hdac3/
mice were digested with increasing concentrations of micrococcal nuclease
(MNase), and genomic DNA was analyzed using agarose gel electrophoresis.
The positions of size markers are shown at the left.
(E) Nucleosome integrity is reduced in Hdac3/ hepatocytes. Cells from
Alb-Cre:Hdac3+/ control and Alb-Cre:Hdac3/ mice were fractionated and
nuclei were extracted with buffer containing the indicated amounts of NaCl
(M). Upper panels show the soluble histone H3 and lower panels show the
histone remaining in the chromatin pellet.
See also Figure S2.
cer Cell 18, 436–447, November 16, 2010 ª2010 Elsevier Inc. 439
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Figure 3. Deletion of Hdac3 Increases H4K5ac,
H4K12ac, and H3K9,K14ac
Western blot analysis of nuclear extracts prepared from
p17 Hdac3-null hepatocytes to examine histone acetyla-
tion and histone methylation levels. H3 and H4 served as
loading controls.
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Hdac3 Is Required for Genomic Stabilityreleased into the cell cycle by the addition of serum to the culture
medium. The level of H4K5ac and H4K12ac was then examined
using western blot analysis of extracts prepared from cells at
various time points after serum addition. After 48 hr of culture
in the absence of serum, the percentage of cells in G0/G1
approached 90% (Figure S3) and H4K5ac and H4K12ac were
reduced to low levels in control cells but remained high in
Hdac3-depleted cells (Figure 4A). After serum addition, both
cultures re-entered the cell cycle, with cells beginning to enter
S phase at 12 hr and over 50% of the cells progressing through
S phase by 18 hr asmeasured by BrdU incorporation (Figure S3).
At 18 and 24 hr after serum addition, H4K5ac and H4K12ac
increased in the control cells, consistent with the acetylation of
these residues on newly synthesized histones that are deposited
on new DNA (Figure 4A). In cells lacking Hdac3, the levels of
acetylation of these residues were already high and increased
only modestly during S phase (Figure 4A). Whereas H3K9,K14
acetylation has not been linked to histone deposition in mamma-
lian cells in themanner that H4K5ac andH4K12ac have, its levels
were low in G0/G1 phase control cells and increased during S
phase. In the absence of Hdac3, H3K9,K14ac was not reduced
upon serum starvation, suggesting that acetylation of these resi-
dues was not removed after S phase, which could account for
the loss of H3K9me3 and reduced heterochromatin in Hdac3-
null livers (Figures 2 and 3).
To better define the requirements for Hdac3 in the removal of
cell-cycle-associated marks, we directly examined H4K5ac in
S phase cells, as this is a classical depositionmark. The punctate
immunofluorescence pattern of PCNA 18 hr after release from
serum starvation was used to identify cells in late S phase, which
are characterized by foci of PCNA at the nuclear periphery (Celis
and Celis, 1985; Madsen and Celis, 1985; Taddei et al., 1999).
Although a general increase in H4K5ac was observed in the
absence of Hdac3 (data not shown), a pronounced increase in
H4K5ac was found in late S phase cells (11% of cells in controls
versus 57% of Hdac3-null cells) (Figure 4B), especially at the
nuclear periphery.
Even relatively modest overexpression or reduced expression
of histones is sufficient to affect genomic stability by causing
DNA double-strand breaks (Gunjan and Verreault, 2003; Olive
and Banath, 1995). Given the apparent high level of H4K5ac in
the nucleus of Hdac3-null cells after S phase (Figures 4A and
4B), we asked what proportion of the total histone H4 is acety-440 Cancer Cell 18, 436–447, November 16, 2010 ª2010 Elsevier Inc.lated in the absence of Hdac3. Two sequential
rounds of immunoprecipitation of lysates pre-
pared from quiescent Hdac3-null NIH 3T3 cells
were performed using anti-H4K5ac to identify
the acetylated histone. Western blot analysis
using anti-H4K5ac confirmed that most of the
acetylated histone was immunopurified in thefirst immunoprecipitation (Figure 4C, upper). The total histone
H4 that was acetylated at K5 was then determined by comparing
the amount of total histone H4 in the immunoprecipitation versus
H4 that remained in the supernatant (Figure 4C, lower). For the
western blot analysis, one-fifth the amount of the supernatant
was loaded as compared to the precipitated H4K5ac. Thus,
roughly 15%–20% of the total histone H4 was acetylated at K5
in control cells and 30%–40% was acetylated in the absence
of Hdac3 (Figure 4C).
Hdac3 Is Required for Genomic Stability
Previously, we noted S phase-associated DNA double-strand
breaks in Hdac3-null cells (Bhaskara et al., 2008). Given the
requirement for Hdac3 in removing histone acetylation marks
that are added during the S phase of the cell cycle and the links
between loss of H3K9me3 and genomic instability, we examined
the consequences of inactivation of Hdac3 to chromosomes
as they progress through mitosis. Metaphase spreads were
prepared from Hdac3FL/+ and Hdac3FL/ MEFs following either
Ad-Cre infection or following tamoxifen treatment of MEFs
carrying the ER-Cre transgene. Both chromosome breaks and
gaps were quantified using cytogenetic analysis. Using either
Ad-Cre (Figure S4) or ER-Cre to delete Hdac3 (Figure 5A) led
to a 5- to 8-fold increase in the average number of breaks and
gaps in metaphase chromosomes when compared to control
cells (Figure 5B), indicating a crucial role for Hdac3 in the main-
tenance of genome stability.
To test whether the DNA damage and genomic instability
phenotypes found in MEFs lacking Hdac3 were recapitulated
in vivo, we examined Alb-Cre:Hdac3+/ and Alb-Cre:Hdac3/
livers for DNA double-strand breaks using immunofluorescence
to detect gH2AX and 53BP1, which localize to sites of DNA
double-strand breaks (Iwabuchi et al., 2003). Whereas there
was little or no endogenous DNA damage in Alb-Cre:Hdac3/
livers at p17 (data not shown), by p28 the Hdac3-null livers dis-
played an increased number of cells with gH2AX and 53BP1
foci when compared to the control hepatocytes (Figure 5C,
0 Gy panels; see Figure S4 for quantification). Subsequently,
we examined DNA repair in Hdac3-null hepatocytes at
p28 following a nonlethal dose of IR (3 Gy). An increased
percentage of cells with a substantial amount of DNA damage
was detected both 1 and 6 hr after IR in Alb-Cre:Hdac3/
when compared to the control Alb-Cre:Hdac3+/ hepatocytes
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Figure 4. Inactivation of Hdac3 Increases H4K5 and H4K12 Acetyla-
tion in Synchronized Cells
(A) Wild-type NIH 3T3 cells (control) or Hdac3FL/ NIH 3T3 cells infected with
Ad-Cre for 48 hr (Hdac3-null) were cultured in 0.5% serum-containing media
for 48 hr. Cells were then transferred tomedia containing 10% fetal calf serum,
and lysates were prepared at the times indicated and analyzed by western blot
tomeasure the levels of the indicated histonemodifications. GAPDH served as
a loading control.
(B) Immunofluorescence analysis of H4K5ac in S phase cells following release
of serum-starved Go/G1 cells into regular media for 18 hr. Late S phase cells
were identified by the punctate pattern of PCNA staining at the nuclear
periphery. Zoomed images of individual nuclei are shown. The scale bar repre-
sents 10 mm.
(C) Immunoprecipitation of quiescent control or Hdac3-null lysates with anti-
H4K5ac and western blot analysis with anti-H4K5ac and anti-H4. P1, first
immunoprecipitation; P2, reimmunoprecipitation of the supernatant from P1;
S, supernatant from P2.
See also Figure S3.
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Hdac3 Is Required for Genomic Stability(Figure 5C). Quantification of 53BP1 foci in 100 cells from two
independent experiments following a 6 hr recovery period
revealed that Hdac3-null cells have a greater percentage of cells
with five to ten foci when compared to the control cells (Fig-
ure S4). We also observed DNA damage even after a 24 hrCanrecovery period in some Alb-Cre:Hdac3/ hepatocytes,
whereas control hepatocytes had repaired the damage caused
by IR treatment (data not shown).
Hdac3-Null Livers Develop Hepatocellular Carcinoma
Analysis of gene expression data obtained previously from Alb-
Cre:Hdac3/ livers at p28 identified an upregulation of genes
that belong to the p53 network (Figure S4), suggesting the
presence of DNA damage. Likewise, quantitative RT-PCR anal-
ysis revealed an upregulation of miRNAs regulated by p53 in
Hdac3-null livers (Figure S4), which is also consistent with the
activation of a DNA damage response (Rokhlin et al., 2008). In
addition, hepatocellular carcinoma (HCC) progression markers,
such as g-glutamyltranspeptidase1 (Pavesi et al., 1989) and
insulin-like growth factor II (Qiu et al., 2008), were upregulated
in the microarray analysis of Alb-Cre:Hdac3/ livers by 2.2-
and 2.7-fold, respectively (Knutson et al., 2008). These data,
coupled with the observed genomic instability, prompted us
to age cohorts of 20 control and 20 Alb-Cre:Hdac3/ mice.
By 15–16 weeks of age, the livers were very pale due to the
dramatic accumulation of neutral lipids and fat caused by inac-
tivation of Hdac3 (Knutson et al., 2008) and contained ‘‘white
nodules’’ when examined by gross morphology (Figure 6A).
These nodules were encapsulated with a fibrous lining that posi-
tively stained with Massion’s trichrome (data not shown) and
appeared to be benign ‘‘adenoma-like’’ structures with the
cytoplasm of the cells filled with microvesicular fluid and an
abundance of mitochondria (Figure 6A and data not shown).
By 8–10 months of age, most of the mice began to show signs
of distress, and necropsy identified the presence of tumors in
the liver. The experiment was humanely terminated for all
mice by 14 months of age (Figure 6B). Pathological analysis
indicated that 20 of 20 mice succumbed to low-grade HCC
at a mean age of 10.2 months (Figure 6B). Immunohistochem-
ical staining for Hdac3 confirmed that the tumors lacked
expression of Hdac3 (Figure 6C) and Ki67 staining confirmed
a high proliferative index in the tumors (Figure 6D). The HCC dis-
played a loss of normal architecture, a trabecular patterning
of cells, a lack of ductal morphology, and very disorganized
features (Figure 6D).
The loss of genomic stability and the impaired response to
DNA damage suggested that a high mutation rate stimulated
the development of HCC (Figures 1, 5, and 6). To begin to assess
what pathways were involved in the formation of HCC, we per-
formed gene expression analysis using cDNA microarrays (Fig-
ure 7A). In the array data, we noted the enhanced expression
of c-Myc, a commonly overexpressed oncogene, which was
confirmed using quantitative RT-PCR (Figure 7B). Signatures
consistent with activation of the Ras pathway and impairment
of the p53 pathway were also identified in this analysis (Fig-
ure 7A). TheWnt pathway has been identified as a key regulatory
node in human HCC and we also noted that this pathway was
affected in the Hdac3-null tumors. Therefore, we examined
b-catenin localization using both cell fractionation and immuno-
histochemical staining. As early as p28, we found increased
amounts of b-catenin localized to the nucleus and there was
prominent nuclear localization of b-catenin in the Hdac3-null
HCCs (Figures 7B and 7C), confirming that this oncogenic
pathway was upregulated in this mouse model of HCC.cer Cell 18, 436–447, November 16, 2010 ª2010 Elsevier Inc. 441
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Figure 5. Loss of Hdac3 Causes Genomic Insta-
bility
(A) Metaphase spreads prepared from ER-Cre:Hdac3FL/+
and ER-Cre:Hdac3FL/ MEFs treated with either vehicle
(top) or tamoxifen (bottom). Magnified views of a group
of chromosomes outlined in the left panels are shown in
the right panels. Arrows indicate broken pieces of chromo-
somes.
(B) The numbers of breaks and gaps observed in control
or null MEFs (Ad-Cre- or tamoxifen-treated ER-Cre:
Hdac3FL/) were quantified, and the data in the graphs
represent the mean ± SD. The numbers of breaks and
gaps per cell were calculated from two differentMEF prep-
arations, in which a total of 50 cells were counted in each
preparation.
(C) DNA repair is impaired in Hdac3-null livers. Hdac3-null
hepatocytes are defective in DNA repair. Mice were irradi-
ated with a 3 Gy dose of IR, and frozen sections of livers
collected immediately or 1 or 6 hr later were prepared for
immunofluorescence analysis of gH2AX and 53BP1.
Arrows indicate Hdac3-null nuclei with 53BP1 foci. The
scale bar represents 20 mm.
See also Figure S4.
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Hdac3 Is Required for Genomic StabilityNCOR1 Is Downregulated in HCC and NCOR
and SMRT Regulate Global Histone Acetylation
Analysis of HDAC3 mRNA levels in four independent human
HCC data sets from the Gene Expression Omnibus (GEO)
database indicated that HDAC3 was reduced in some cases442 Cancer Cell 18, 436–447, November 16, 2010 ª2010 Elsevier Inc.(Figure 8; Figure S5).HDAC3 is highly expressed
in cycling cells (e.g., in the crypt regions of the
colonic epithelium) (Spurling et al., 2008; Wilson
et al., 2006), so comparing quiescent normal
tissue to cycling cancer cells may underesti-
mate the level of its loss of expression. Never-
theless, in the largest data set, HDAC3 levels
were reduced by 1.5-fold in 13% of the cases
and over 2-fold in 3.3% of the cases as
compared to normal controls (data not shown
and Figure 8A). There was no association with
hepatitis C or hepatitis B viral infection or
survival (data not shown). Given that HDAC3 is
dormant until activated by association with
NCOR or SMRT (Guenther et al., 2001) and
that it is recruited to chromatin through associa-
tion with other factors, we probed the GEOHCC
data sets for changes in expression of the 57
direct interaction partners of HDAC3 identified
in the Human Protein Reference Database
(Table S1). Four of these genes (STAT3, GTF2I,
GCM1, and NCOR1) showed reduced expres-
sion in HCC. NCOR1 is not only downregulated
but is also located on a region of chromosome
17p that is deleted in human HCC (Xu et al.,
2001). The levels of NCOR1 were reduced by
2-fold or greater in nearly one-third of HCC
samples in the largest data set (Figure 8A) and
were similarly downregulated in the majority of
the samples in smaller HCC gene expression
data sets (Figure S6). Using immunohistochem-istry to detect nuclear NCOR1, we found that two-fifths of the
human HCCs tested had reduced levels of NCOR1 (Figure 8B),
which is consistent with the mRNA expression results.
Given that NCOR/SMRT directly control HDAC3 functions
(Guenther et al., 2001), we used siRNAs to probe the
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Figure 6. Loss ofHdac3 Leads toHepatocel-
lular Carcinoma
(A) Representative livers of 5-month-old (middle)
and 10-month-old (right) Alb-Cre:Hdac3/ mice.
(B) Survival plot for Alb-Cre:Hdac3/ mice.
Heterozygous mice showed no mortality within
this time frame.
(C) Immunohistochemistry using anti-Hdac3 shows
that normal hepatocytes express Hdac3 (left),
whereas Alb-Cre:Hdac3/ mice lack Hdac3 both
in the tumor and surrounding tissue. T, tumor; L,
liver. The scale bar represents 60 mm.
(D) Hematoxylin and eosin-stained histological
sections (H&E; top) and immunohistochemistry
for Ki67 (bottom) from 10-month-old Alb-Cre:
Hdac3/mice. The scale bar represents 60 mm.
See also Figure S5.
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Hdac3 Is Required for Genomic Stabilityrequirements for these HDAC3 cofactors in the regulation of
histone acetylation. In HeLa cells that express both family
members, depletion of either NCOR or SMRT alone had only
modest effects on global histone acetylation (data not shown).
Targeting both family members together caused a small
increase in H4K5ac (Figure 8C). However, even though NCOR/
SMRT levels were only reduced by about 50%, there was
a significant accumulation in the levels of global H4K5ac in
both HeLa cells (Figure 8C) and NIH 3T3 cells (Figure S6B).
These increases in histone acetylation were associated with
a decrease in the levels of HDAC3 detected in both HeLa and
NIH 3T3 cells (Figure 8C; Figure S6C). Immunofluorescence
using anti-PCNA to identify S phase cells demonstrated a
5-fold increase in the number of cells with high levels of
H4K5ac at the nuclear periphery in late S phase cells targeted
with siRNAs to both cofactors (Figure 8D; Figure S6C). Given
this alteration in histone marks, we examined these cells for
DNA double-strand breaks using anti-53BP1. Cells depleted of
NCOR1 and SMRT showed a dramatic increase in the number
of cells with greater than ten foci (Figure 8E; Figure S6D). Collec-
tively, these results show that the NCOR/SMRT/HDAC3 axis is
required for removing histone marks globally and maintaining
genomic stability.Cancer Cell 18, 436–447, NDISCUSSION
The increase in acetylation of H4K5,
H4K12, H4K16, and H3K9,K14 that was
observed upon inactivation of Hdac3,
along with the concomitant loss of
H3K9me3, provides a likely mechanism
for the failure to maintain chromatin struc-
ture inHdac3-null mice (Figure 2). H4K5ac
and H4K12ac are associated with histone
deposition (Sobel et al., 1995), especially
in heterochromatic regions that are repli-
cated late in S phase (Taddei et al.,
1999), and this pattern was accentuated
in the absence of Hdac3 or when NCOR/
SMRT were targeted using siRNAs
(Figures 4 and 8). The removal of these
marks is required for propagation ofheterochromatin in yeast (Zhou et al., 2009), which suggests
that the accumulation of these marks (and the reduced levels
of H3K9me3) may be the underlying cause for the reduction
in heterochromatin in the Hdac3-null livers. Indeed, loss of
H3K9me3 impaired theDNAdamage response, and the inactiva-
tion of the murine H3K9 methyltransferases or mutation of HP1b
caused genomic instability, defects in double-strand-break
repair, and an increased tumor risk (Aucott et al., 2008; Kondo
et al., 2008; Luijsterburg et al., 2009; Peters et al., 2001; Sun
et al., 2009). This suggests that the failure to maintain a normal
chromatin structure underlies the Hdac3/-associated defects
in two distinct types of DNA repair (NHEJ and HR), and in
genomic stability (Figures 1 and 5), which ultimately led to tumor
development (Figure 6).
The siRNA-mediated knockdown of NCOR/SMRT, like dele-
tion of Hdac3, caused the accumulation of histone deposition
marks, suggesting that these Hdac3-activating factors also
play an intrinsic role during the cell cycle. NCOR and SMRT
were initially identified as transcriptional corepressors associ-
ated with nuclear hormone receptors (Chen and Evans, 1995;
Horlein et al., 1995; Karagianni and Wong, 2007), as well as
with a variety of DNA-binding factors (Perissi et al., 2004).
However, the function of these corepressors during the cell cycleovember 16, 2010 ª2010 Elsevier Inc. 443
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Figure 7. b-Catenin Is Misregulated in Hdac3-Null HCC
(A) Heat map of selected genes from a cDNA microarray analysis of control
liver and Hdac3-null HCCs. The levels of mRNAs expressed from genes asso-
ciated with the Ras, p53, and Wnt pathways are depicted as green (low) or red
(high), where black indicates no change.
(B) Quantitative RT-PCR confirmation of the microarray results. The graph
shows the expression levels of the indicated genes obtained on the microar-
rays and from quantitative RT-PCR as the average fold increase or decrease
over controls that were set to 1 ± SD.
(C) b-catenin is mislocalized in Hdac3-null livers. Control and p28 Hdac3-null
hepatocytes were separated into cytoplasmic (C) and nuclear (N) fractions
and b-catenin was detected by immunoblot. Tubulin was used tomonitor cyto-
plasmic contamination of nuclei.
(D) b-catenin is nuclear in Hdac3-null HCC. Immunohistochemistry was used
to determine the cellular localization of b-catenin (brown tint). Nuclei were
counterstained with hematoxylin (blue tint). Arrows indicate cells with promi-
nent nuclear b-catenin. The scale bar represents 20 mm.
See also Table S1.
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Hdac3 Is Required for Genomic Stabilitymay represent the ancestral activity of these complexes. We
speculate that during evolution this cell-cycle machinery was re-
cruited in higher organisms to regulate gene expression patterns
in a cell-type-specific manner (e.g., in response to nuclear
hormones) or to form heterochromatin to more permanently
silence gene expression.
Although HDAC3 has been suggested to be overexpressed in
colorectal carcinoma (Spurling et al., 2008; Wilson et al., 2006), it444 Cancer Cell 18, 436–447, November 16, 2010 ª2010 Elsevier Incis not amplified at the DNA level. In addition, HDAC3 is
expressed at higher levels in the proliferating cells of the colonic
crypts, whichmight suggest that its levels are higher in colorectal
carcinoma because the cells are cycling. Conversely, it is
notable that HDAC3 lies within a region of chromosome 5q31.3
that is frequently deleted in breast cancer (Johannsdottir et al.,
2006) andmyelodysplastic syndromes (Ebert, 2009). Intriguingly,
NCOR1 lies in a region of chromosome 17 that is frequently
deleted in HCC (Mahlknecht et al., 1999), and an analysis of
expression profiles indicated that downregulation of NCOR1
expression is common in a subset of humanHCC (Figure 8A; Fig-
ure S6). Our data are consistent with the inactivation of the
HDAC3/NCOR/SMRT axis, possibly contributing to a subset of
human cancer by allowing the increase of histone acetylation
during the S phase, leading to DNA damage and further accumu-
lation of mutations.
Nearly all nontargeted cancer therapeutics (i.e., those that do
not target amutant protein that initiates a cancer) develop a ther-
apeutic window by acting on cycling cells to cause DNA damage
(Ashwell and Zabludoff, 2008; Lieberman, 2008). However, one
side effect is that these agents, when given at too high a dose
or for too long, also cause genomic instability in normal cells,
leading to therapy-associated secondary cancers. Our results
raise this possibility for HDIs, all of which currently target
HDAC3. However, compounds such as SAHA appear to be
well tolerated, possibly owing to their short half-life in vivo (Butler
et al., 2000). That is, SAHA may cause S phase-associated DNA
damage for those cancer cells in S phase during the 4–6 hr
window in which the daily dose of SAHA is active, but only cause
mild problems for themajority of normal cells that are not cycling.
In addition, normal cells that are proliferating, such as in the
gastrointestinal tract and in the bone marrow, can either repair
the DNA damage or their chromatin is ‘‘reset’’ after the SAHA
is metabolized. Thus, we predict that although continuous inhibi-
tion of Hdac3 is detrimental (e.g., Figure 6), transient inhibition,
even when frequently repeated, may be safe.
EXPERIMENTAL PROCEDURES
See Supplemental Experimental Procedures for additional methods used.
Mice
Miceharboringeitheraconditional floxed (FL)alleleoranull () allelewerecreated
as described previously (Knutson et al., 2008). To create liver-specific Hdac3
knockout mice, mice with a floxed or a null allele were crossed to transgenic
mice expressing Alb-Cre (Knutson et al., 2008) to obtain Alb-Cre:Hdac3+/ and
Alb-Cre:Hdac3/ offspring mice. All experiments using mice were approved
by the Vanderbilt University Institutional Animal Care and Use Committee.
DNA Repair Assays
DNA repair assays were performed using HEK293 cells engineered with inte-
grated reporters for both types of double-strand-break repair (Zhuang et al.,
2009). Briefly, cells (1 3 105) were transfected twice with HDAC3 siRNA using
Oligofectamine (Invitrogen). pCMV-I-Sce1 or the control vector was trans-
fected into the cells using FuGene 6 (Roche). The cells were either analyzed
by two-color FACS analysis to examine homologous recombination or PCR
was used to determine the rate of NHEJ-mediated repair (see Supplemental
Experimental Procedures for primer sequences).
Transmission Electron Microscopy
Liver tissue was minced into fine pieces and fixed in 2.5% glutaraldehyde in
0.1 M cacodylate buffer at room temperature for 1–2 hr. Samples were then
washed in 0.1 M cacodylate buffer and treated with 1% aqueous osmium.
AC
B
C
HDAC1
HDAC3
NCOR1
NCOR2
D
NT
N/S
Hoechst PCNA H4K5ac
Hoechst 53BP1
NT
N/S
E
N
T
Hdac3
H4K5ac
GAPDH
NCoR
H4
SMRT
H4K12ac
N
/S
H4K16ac
H4
Normal HCC
NCoR NCoR
Color Key
-2 -1 0 1 2 3
Figure 8. NCOR1 Is Downregulated in
Human HCC and siRNA Targeting of NCOR
and SMRT Causes DNA Damage
(A) Heat map representation of the analysis of
NCOR1, NCOR2, Hdac3, and Hdac1mRNA levels
in human HCC samples (GEO 5975 data set).
Green depicts low expression relative to the
mean of control samples and red indicates higher
expression. A 2-fold cutoff was used to define
a significant change.
(B) NCOR1 is downregulated in a subset of human
HCCs. Immunohistochemical staining was used to
detect NCOR1 in human HCC or normal matched
surrounding tissue (brown stain). Cells were coun-
terstained with hematoxylin (blue tint). The scale
bar represents 20 mm.
(C) HeLa cells were transfected with either nontar-
geting (NT) or NCOR/SMRT siRNA (N/S). Whole-
cell lysates were analyzed for histone modifica-
tions using western blot.
(D) Immunofluorescence analysis of H4K5 acetyla-
tion in HeLa cells transfected with either nontar-
geting (NT) or NCOR/SMRT siRNA (N/S). The scale
bar represents 10 mm. S phase cells were identi-
fied by the punctate pattern of PCNA staining.
(E) Immunofluorescence analysis of 53BP1 in
HeLa cells transfected with either nontargeting
siRNA (NT) or NCOR/SMRT siRNA (N/S). The scale
bar represents 10 mm.
See also Figure S6.
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Hdac3 Is Required for Genomic Stabilitytetraoxide. Tissues were then washed, dehydrated, and embedded in Spurr
resin. Thin sections (100 nm) were viewed with an FEI CM-12 transmission
electron microscope operated at 80 KeV.
Gene Expression Analysis of Human HCC Samples
Four HCC and normal control experiments (GSE14323, GSE6764, GSE6222,
and GSE5975) were selected from the Gene Expression Omnibus database
(http://www.ncbi.nlm.nih.gov/geo) (Barrett et al., 2009). The description of
this analysis is elaborated in Supplemental Experimental Procedures. For
GSE6764 (Wurmbach et al., 2007), we compared the normal liver samples
with HCC samples of different stages. For GSE6222 (Liao et al., 2008), weCanexcluded the HuH7 cell line data. GSE1898 was excluded from this analysis
due to variations in the probe sets. Expression data generated from murine
tumors lacking Hdac3 are found in GSE22457.
Protein Analyses
For preparation of whole-cell protein extracts, the cell pellet was washed with
PBS and sonicated in RIPA buffer (0.5% Triton X-100, 0.5% deoxycholic acid,
and 0.5%SDS in PBS) with protease inhibitors (0.5 mMPMSF, 2 mg/ml leupep-
tin, and 15 mg/ml aprotinin) prior to western analyses. Antibodies used and the
preparation of nuclear extracts are described in Supplemental Experimental
Procedures.cer Cell 18, 436–447, November 16, 2010 ª2010 Elsevier Inc. 445
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Expression data generated from murine tumors lacking Hdac3 have been
deposited in the Gene Expression Omnibus database under accession
number GSE22457.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at
doi:10.1016/j.ccr.2010.10.022.
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